Benjamin Rich

Benjamin Rich is the Director of Cell Biology at Celcuity, Inc., a biotechnology company focused on developing diagnostic tests and therapies for cancer.1 He brings extensive experience in cell biology and cancer research to his role at Celcuity.

Professional Background

Benjamin Rich is based in Boston, Massachusetts.3 Prior to joining Celcuity, he gained valuable experience working at Dana-Farber Cancer Institute, a renowned cancer research and treatment center.3 This background likely contributes to his expertise in oncology-related cell biology research.

Contributions at Celcuity

At Celcuity, Benjamin Rich has been involved in several important research projects and publications:

1. He co-authored a study published in the Journal of Cancer Research and Clinical Oncology in 2020, which identified a new HER2-negative breast cancer subtype that may be responsive to anti-HER2 therapy.2

2. Rich also contributed to research presented at the 2018 San Antonio Breast Cancer Symposium, evaluating pan-HER and c-MET inhibitors in HER2-negative breast cancer cells.2

These contributions highlight his involvement in Celcuity's work on developing novel diagnostic approaches and potential treatment strategies for cancer, particularly in breast cancer research.

Research Profile

Benjamin Rich maintains a research profile on ResearchGate, indicating his active engagement in the scientific community and ongoing contributions to cell biology research.4 His work at Celcuity focuses on advancing the company's CELsignia diagnostic platform, which aims to identify new cancer subtypes and guide more personalized treatment approaches.

It's worth noting that while there is a Dr. Benjamin J. Rich who is an assistant professor of radiation oncology at the University of Miami Miller School of Medicine5, this appears to be a different individual from the Benjamin Rich at Celcuity.